பெண்ணோயியல் & மகப்பேறியல்
திறந்த அணுகல்

சுருக்கம்

Does the Use of Highly Purified Human Menopausal Gonadotrophin (HP-HMG) avoid Ovarian Hyperstimulation Syndrome (OHSS) in Polycystic Ovary (PCO) Patients in Assisted Reproduction (IVF/ICSI)?

Elmahaishi Asma and Mohammed Said Elmahaishi

Objective: To evaluate the role of highly purified HMG (Diclair from BBT) in preventing OHSS in polycystic ovary (PCO) patients.
Design: Prospective study from 1st Aug, 2012 until end of July, 2013 for one year.
Setting: Lamis IVF center, Misurata LIBYA.
Patient(s): During one year of study, 800 patients were treated for ICSI procedure. The 20% from these cases were diagnosed as polycystic ovary.
Main outcome measure(s): Diagnosed of polycystic ovary, Age distribution, Fixed dose of 450 Iu of HP HMG from BBT/day, IVF outcome and any OHSS or admission.
Result(s): age distribution counted from 20 yrs to 44 yrs old. Their eggs and embryos Quality were very good. Pregnancy rate and presence of OHSS.
Conclusion: using highly purified HMG is safe in polycystic ovary patient and can reduce or prevent the OHSS with uneffective pregnancy outcome rate.